Robert Nelsen

Robert Nelsen

Vermögen: 2 Mio $ am 31.05.2026

62 Jahre
Health Technology
Commercial Services
Finance

Profil

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.
Some of his notable early-stage investments include Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), June Therapeutics (JUNO – acquired by Celgene), Beam Therapeutics (BEAM), Karuna Therapeutics (KRTX), Altos Labs, EQRx (EQRX), National Resilience, Prime Medicine, Lyell Immunopharma (LYEL), Array BioPharma (ARRY – acquired by Pfizer), Hua Medicine (2552:HK), Vir Biotechnology (VIR), Insitro, Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), GRAIL (acquired by Illumina), Gossamer Bio (GOSS), Ikaria (acquired by Mallinckrodt), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), Receptos (RCPT – acquired by Celgene), Aviron (AVIR – acquired by MedImmune), Denali Therapeutics (DNLI), Syros Pharmaceuticals (SYRS), Sana Biotechnology (SANA), Verve Therapeutics (VERV), Brii Biosciences (2137:HK), Bluebird Bio (BLUE), R2 Technology (acquired by Hologic), Caliper Life Sciences (CALP – acquired by PerkinElmer), Trubion Pharmaceuticals (TRBN – acquired by Emergent Biosolutions), Adolor (ADLR – acquired by Cubist Pharmaceuticals), deCODE Genetics (DCGN – acquired by Amgen), Editas (EDIT), 10x Genomics, Semma Therapeutics (acquired by Vertex Pharmaceuticals), Element, and IDUN Pharmaceuticals (acquired by Pfizer).
Mr. Nelsen is a director of VIR, SANA, LYEL, National Resilience, Insitro, Prime Medicine, Nutcracker Therapeutics, Neumora Therapeutics, Brii Biosciences, and serves as Chairman of Hua Medicine, among others.
He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute of Systems Biology, and was a director of the National Venture Capital association.
Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S.
from the University of Puget Sound with majors in Economics and Biology.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
31.03.2025 60 615 ( 0,06 % ) 2 Mio $ 31.05.2026
05.06.2026 100 142 ( 0,06 % ) 355 504 $ 31.05.2026
31.12.2024 150 000 ( 0,01 % ) 50 336 $ 31.05.2026
04.06.2026 13 853 ( 0,01 % ) 45 715 $ 31.05.2026

Aktive Positionen von Robert Nelsen

UnternehmenPositionBeginn
HUA MEDICINE (SHANGHAI) LTD. Vorsitzender 23.04.2010
PRIME MEDICINE, INC. Direktor/Vorstandsmitglied 01.09.2020
SANA BIOTECHNOLOGY, INC. Gründer 13.07.2018
Gründer 28.06.2010
Direktor/Vorstandsmitglied 01.01.2022
Vorsitzender -
Hua Medicine Technology (Hong Kong) Ltd.
Direktor/Vorstandsmitglied 01.08.2010
Direktor/Vorstandsmitglied -
Direktor/Vorstandsmitglied -
░░░░ ░░░░░░░ ░░░░░░░░ ░░ ░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░ ░░░░░ ░░░░░ ░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░

Ehemalige bekannte Positionen von Robert Nelsen

UnternehmenPositionEnde
░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░ ░░░░░░░░ ░░░░░░░░░░
Sehen Sie sich die Erfahrung von Robert Nelsen im Detail an

Ausbildung von Robert Nelsen

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

63

Beziehungen ersten Grades

80

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen80

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Finance

Finance

Process Industries

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Energy Minerals

Health Technology

Health Technology

Health Technology

Producer Manufacturing

Health Technology

Miscellaneous

Consumer Services

Technology Services

Consumer Services

Finance

Health Technology

Commercial Services

Health Technology

Commercial Services

Commercial Services

Commercial Services

Finance

Commercial Services

Health Technology

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Technology Services

Health Technology

Hua Medicine Technology (Hong Kong) Ltd.

Health Technology

Health Technology

Health Technology

Commercial Services

Finance

Health Technology

Health Services

Health Technology

Health Technology

Finance

Commercial Services

Brii Biosciences (Beijing) Co. Ltd.

Brii Biosciences (Hong Kong) Co. Ltd.

Health Technology

Finance

Health Technology

Health Technology

Technology Services

Health Technology

Technology Services

  1. Börse
  2. Insiders
  3. Robert Nelsen